GRADE summary of evidence for thrombolysis followed by AC vs AC alone in patients with RAT
| No. of studies . | Study design . | No. of patients (%) . | Effect . | Certainty . | Importance . | ||
|---|---|---|---|---|---|---|---|
| Thrombolysis followed by AC . | AC alone . | Relative (95% CI) . | Absolute (95% CI) . | ||||
| Mortality (assessed with: all-cause mortality) | |||||||
| 227,28 | Nonrandomized studies | 2/11 (18.2) | 1/13 (7.7) | RD, 0.02 (−0.30 to 0.34) | 20 more per 1000 (300 fewer to 340 more) | ⊕○○○ Very low∗,†  | Critical | 
| Thrombus resolution (assessed with: complete or partial resolution) | |||||||
| 322,27,28 | Nonrandomized studies | 15/17 (88.2) | 25/27 (92.6) | RR, 1.01 (0.84-1.22) | 9 more per 1000 (148 fewer to 204 more) | ⊕○○○ Very low∗,†  | Critical | 
| Thrombus recurrence | |||||||
| 122 | Nonrandomized studies | 0/6 (0.0) | 0/14 (0.0) | Not estimable | Not estimable | ⊕○○○ Very low∗,†  | Critical | 
| Bleeding (assessed with: unspecified) | |||||||
| 127 | Nonrandomized studies | 2/4 (50.0) | 0/9 (0.0) | Not estimable | Not estimable | ⊕○○○ Very low∗,†  | Critical | 
| Major bleeding | |||||||
| 122 | Nonrandomized studies | 1/6 (16.7) | 1/14 (7.1) | RR, 2.33 (0.17-31.46) | 95 more per 1000 (59 fewer to 1000 more) | ⊕○○○ Very low∗,†  | Critical | 
| Clinically relevant non major bleeding | |||||||
| 122 | Nonrandomized studies | 0/6 (0.0) | 0/14 (0.0) | Not estimable | Not estimable | ⊕○○○ Very low∗,†  | Critical | 
| No. of studies . | Study design . | No. of patients (%) . | Effect . | Certainty . | Importance . | ||
|---|---|---|---|---|---|---|---|
| Thrombolysis followed by AC . | AC alone . | Relative (95% CI) . | Absolute (95% CI) . | ||||
| Mortality (assessed with: all-cause mortality) | |||||||
| 227,28 | Nonrandomized studies | 2/11 (18.2) | 1/13 (7.7) | RD, 0.02 (−0.30 to 0.34) | 20 more per 1000 (300 fewer to 340 more) | ⊕○○○ Very low∗,†  | Critical | 
| Thrombus resolution (assessed with: complete or partial resolution) | |||||||
| 322,27,28 | Nonrandomized studies | 15/17 (88.2) | 25/27 (92.6) | RR, 1.01 (0.84-1.22) | 9 more per 1000 (148 fewer to 204 more) | ⊕○○○ Very low∗,†  | Critical | 
| Thrombus recurrence | |||||||
| 122 | Nonrandomized studies | 0/6 (0.0) | 0/14 (0.0) | Not estimable | Not estimable | ⊕○○○ Very low∗,†  | Critical | 
| Bleeding (assessed with: unspecified) | |||||||
| 127 | Nonrandomized studies | 2/4 (50.0) | 0/9 (0.0) | Not estimable | Not estimable | ⊕○○○ Very low∗,†  | Critical | 
| Major bleeding | |||||||
| 122 | Nonrandomized studies | 1/6 (16.7) | 1/14 (7.1) | RR, 2.33 (0.17-31.46) | 95 more per 1000 (59 fewer to 1000 more) | ⊕○○○ Very low∗,†  | Critical | 
| Clinically relevant non major bleeding | |||||||
| 122 | Nonrandomized studies | 0/6 (0.0) | 0/14 (0.0) | Not estimable | Not estimable | ⊕○○○ Very low∗,†  | Critical |